Literature DB >> 32241798

Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study.

Fang-Xiao Zhu1, Jing-Yang Huang2,3, Zhizhong Ye4, Qing-Qing Wen1, James Cheng-Chung Wei5,6,7,8,9.   

Abstract

BACKGROUND: Idiopathic thrombocytopenic purpura (ITP) may play a role in early-stage systemic lupus erythematosus (SLE). The incidence of SLE in patients with ITP and the potential relationship between them is still unclear. This study was performed to provide epidemiological evidence regarding the relationship between ITP and SLE occurrence.
METHODS: In this population-based retrospective cohort study, the risk of SLE was analysed in a cohort of patients newly diagnosed with ITP between 2000 and 2013. Controls were selected at a 1:2 ratio through propensity score matching (PSM) using the greedy algorithm. The Cox proportional hazard model was used to analyse the association between ITP and SLE incidence. There were four different Cox regression models, and the sensitivity analyses were implemented to evaluate the HR of SLE after exposure with ITP.
RESULTS: In the age-matched and sex-matched ITP and non-ITP cohort, the average follow-up time was about 80 months in this study. There were 34 (4.70%) and 27 (0.19%) incident cases of SLE in ITP and non-ITP group. The incidence rates were 62.0 (95% CI 44.3 to 86.8) and 2.10 (95% CI 1.44 to 3.06), respectively. The adjusted HR of incidental SLE in the ITP group was 25.1 (95% CI 13.7 to 46.0). The other risk factors for SLE were female sex and Sjogren's syndrome. After PSM, the incidence rate and Kaplan-Meir curves of SLE were consistent with the results for the age-matched and sex-matched population, the HR 17.4 (95% CI 5.28 to 57.4) was estimated by conditional Cox model.
CONCLUSION: This cohort study demonstrated that patients with ITP have a higher risk of SLE. Clinically, patients with ITP should be monitored for incidental lupus. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  autoimmune diseases; epidemiology; systemic lupus erythematosus

Mesh:

Year:  2020        PMID: 32241798     DOI: 10.1136/annrheumdis-2020-217013

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   27.973


  4 in total

1.  Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children.

Authors:  Yuqing Song; Yuelun Zhang; Zhuo Li; Jing Liu; Juan Xiao; Hongmei Song
Journal:  Ann Hematol       Date:  2022-05-09       Impact factor: 3.673

2.  ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases.

Authors:  Yuan Liu; Shiju Chen; Guomei Yang; Bin Wang; Jinying Lan; Fan Dai; Peishi Rao; Puqi Wu; Hongyan Qian; Guixiu Shi
Journal:  Lupus Sci Med       Date:  2021-10

3.  Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia.

Authors:  Soo Min Ahn; Eun-Ji Choi; Ji Seon Oh; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo; Seokchan Hong
Journal:  Arthritis Res Ther       Date:  2022-09-06       Impact factor: 5.606

4.  Risk of Systemic Lupus Erythematosus in Patients With Anti-phospholipid Syndrome: A Population-Based Study.

Authors:  Hsin-Hua Chen; Ching-Heng Lin; Wen-Cheng Chao
Journal:  Front Med (Lausanne)       Date:  2021-05-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.